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strand and positioning Dcr-2 near the 5¶ end
of the strand to be loaded into the RISC. In
this model, R2D2, as a component of the
Dcr-2/R2D2 heterodimer, is the primary protein
sensor of siRNA thermodynamic asymmetry.
How does the RLC, with the Dcr-2/R2D2
heterodimer positioned asymmetrically on
the siRNA, progress to the RISC? Argonaute
2 (Ago2) is a È130-kD protein that is a core
component of the RISC (22) and is required
for siRNA unwinding (14). We found that a
È130-kD protein was crosslinked to siRNA
when the guide strand contained 5-iodouracil
at p20 (asterisk in Fig. 2C, siRNAs c, d, e,
and g). The È130-kD protein was photo-
crosslinked only to the guide strand of the
siRNA (Fig. 4), which suggests that this
protein is a component of the RISC. The
È130-kD protein was immunoprecipitated
with antibodies to Ago2 but not to Ago1 (fig.
S3A) and was not observed in embryos lacking
both maternal and zygotic Ago2 (ago2414, fig.
S3B). Thus, the È130-kD protein is Ago2.
When R2D2 and Ago2 were photocross-
linked to siRNAs b or e (which contain 5-
iodouracil at p20 of the passenger or the
guide strand), R2D2 was bound to the 3¶
end of the guide strand and Dcr-2 to the 3¶
end of the passenger strand at early times in
the reaction (Fig. 4A). Later, binding of R2D2
and Dcr-2 decreased concurrently, accompa-
nied by a corresponding increase in binding of
Ago2 to the 3¶ end of the guide strand. In
ago2414 lysates, R2D2 binding to the 3¶ end of
the guide strand and Dcr-2 binding to the 3¶
end of the passenger strand did not decrease
with time (fig. S4A); this finding suggests
that binding of Ago2 facilitates the release of
the heterodimer from siRNA.
The siRNA bound by Ago2 is single-
stranded, because Ago2, when photocross-
linked to siRNA, was captured by a tethered
2¶-O-methyl oligonucleotide complementary
to the siRNA guide strand (Fig. 4B) (23), as
has been observed for the RISC (7, 23–25).
R2D2 was not captured by the 2¶-O-methyl
oligonucleotide, but was instead recovered in
the supernatant, consistent with R2D2 bind-
ing of double-stranded siRNA.
Our data suggest a model for RISC
assembly. First, R2D2 orients the Dcr-2/
R2D2 heterodimer on the siRNA within the
RLC. As siRNA unwinding proceeds, the
heterodimer is exchanged for Ago2, the core
component of the RISC. Indeed, we cannot
detect single-stranded siRNA in the RLC
assembled in ago2414 lysate (fig. S4, B and
C). We hypothesize that unwinding occurs
only when Ago2 is available, so that siRNA
in the RLC is unwound only when the RISC
can be assembled.
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The Human Polyomavirus, JCV,
Uses Serotonin Receptors
to Infect Cells
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The human polyomavirus, JCV, causes the fatal demyelinating disease pro-
gressive multifocal leukoencephalopathy in immunocompromised patients. We
found that the serotonergic receptor 5HT2AR could act as the cellular receptor
for JCV on human glial cells. The 5HT2A receptor antagonists inhibited JCV
infection, and monoclonal antibodies directed at 5HT2A receptors blocked
infection of glial cells by JCV, but not by SV40. Transfection of 5HT2A
receptor–negative HeLa cells with a 5HT2A receptor rescued virus infection, and
this infection was blocked by antibody to the 5HT2A receptor. A tagged 5HT2A
receptor colocalized with labeled JCV in an endosomal compartment following
internalization. Serotonin receptor antagonists may thus be useful in the
treatment of progressive multifocal leukoencephalopathy.
The incidence of progressive multifocal leuko-
encephalopathy (PML) has increased 50-fold
since 1979 and now affects nearly 1 in every
200,000 persons (1). The disease is due to
infection of oligodendrocytes by the com-
mon human polyomavirus, JCV (2). Initial
infection with JCV occurs early in childhood
and eventually reaches a seroprevalence of
between 70 and 80% in the adult population.
The initial infection is subclinical, and the
virus establishes a lifelong persistent infec-
tion. At any given time, È5% of the
population is actively excreting virus in the
urine, and JCV is a frequent contaminant of
untreated human sewage (3). PML occurs
almost exclusively in severely immunosup-
pressed patients. The majority of cases occur
in patients with AIDS, and to date there is no
effective treatment (4). PML is initiated
when JCV traffics from peripheral sites, such
as the kidney and lymphoid organs, to the
central nervous system (CNS) by unknown
mechanisms. There is a strong association
between JCV and human B lymphocytes,
and the virus may traffic to the CNS in an
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infected B cell (5–7). Once in the CNS, JCV
infects both oligodendrocytes and astrocytes.
N-linked glycoproteins containing termi-
nal alpha 2-6–linked sialic acid are a critical
component of the JCV receptor (8). The
tissue distribution of this receptor-type sialic
acid strongly correlates with the known
tropism of JCV for oligodendrocytes, astro-
cytes, B-lymphocytes, and kidney epithelial
cells (9). JCV receptor interactions play a
critical role in tropism, because a hybrid SV40
virus containing JCV capsid proteins main-
tains the restricted host range of JCV (10).
Also, unlike the related polyomavirus SV40,
which enters cells by caveolae-dependent
endocytosis, JCV enters cells by a ligand-
inducible clathrin-dependent pathway (11–15).
Chlorpromazine, which blocks clathrin-
dependent endocytosis, and the related com-
pound clozapine effectively block JCV
infection of glial cells (16 ). Both chlorprom-
azine and clozapine belong to a class of drugs
known as serotonin-dopamine inhibitors
(SDIs). Because glial cells express receptors
for both dopamine and serotonin (Fig. 1A), we
hypothesized that JCV may use either sero-
tonin receptors or dopamine receptors to infect
glial cells. To test this hypothesis, glial cells
were treated with increasing concentrations of
the dopamine antagonists bromocriptine and
minaprine, and a dopamine agonist, pergolide.
These agents have generally minimal activity
against serotonin receptors (17, 18). Glial cells
were also treated with increasing concentra-
tions of antagonists with activity against both
dopamine and serotonin receptors (19, 20).
These included metoclopramide, chlorprom-
azine, and clozapine. The cells were then
incubated with JCV at a multiplicity of
infection (MOI) of 1.0 in the continued pres-
ence of drug. At 72 hours after infection, the
cells were assayed for viral infection. The
dopamine-specific antagonists, bromocriptine
and minaprine, and the dopamine agonist,
pergolide, had little to no effect on the infec-
tivity of glial cells by JCV (Fig. 1B). In con-
trast, metoclopramide, chlorpromazine, and
clozapine, which antagonize the 5HT2 sero-
tonergic receptors, all significantly inhibited
infection (Fig. 1B). Because these reagents are
not highly specific, we next asked whether
5HT itself or selective 5HT2 receptor antag-
onists could inhibit JCV infection. Glial cells
were treated in triplicate with increasing
concentrations of 5HT (which down-regulates
serotonin receptors), MDL100.907 (which se-
lectively inhibits 5HT
2A
R), SB206553 (which
inhibits 5HT
2C
R), ketanserin (which inhibits
5HT
2A
R and 5HT
2C
R), or ritanserin (which
inhibits 5HT
2A
R, 5HT
2B
R, and 5HT
2C
R)
(21–25). 5HT and MDL100.907 both inhib-
ited infection of glial cells by JCV at con-
centrations of 1.0 mM (Fig. 1B). The 5HT
2C
inhibitor SB206553 only slightly inhibited
infection when used at 1.0 mM (Fig. 1B).
The 5HT
2A
and 5HT
2C
inhibitor ketanserin
inhibited infection at 0.1 mM, and ritanserin
also inhibited at 0.1 mM (Fig. 1B).
We next asked whether antibodies direct-
ed at 5HT
2A
R, 5HT
2C
R, or at the D1, D2,
and D3 dopamine receptors could block in-
Fig. 1. (A) Glial cells express receptors for both serotonin and dopamine. Glial cells were incubated
with irrelevant antibody (solid histograms), with monoclonal antibodies to the 5HT2A and 5HT2C
serotonergic receptors (top panels, open histograms), or with polyoclonal antibodies to the D1, D2,
D2s, and D3 dopamine receptors (middle and bottom panels, open histograms). Antibody binding
was detected with either goat anti-mouse or goat anti-rabbit secondary antibodies conjugated to
AlexaFluor-488. (B) SDIs inhibited infection of glial cells by JCV. Glial cells were incubated with the
dopamine antagonists bromocriptine and minaprine, a dopamine agonist, pergolide, or with
metoclopramide, chlorpromazine, or clozapine, which antagonize both dopamine receptors and
serotonin receptors. Cells were then challenged with JCV and infection scored at 72 hours after
infection by indirect immunofluorescence assay of V antigen–expressing cells. The percentage of
infected cells in untreated cultures was set at 100%. The ability of these agents to inhibit JCV
infection correlate with their ability to antagonize 5HT2A and 5HT2c serotonin receptors. (Bottom
panel) 5HT and specific 5HT2 antagonists inhibited infection of glial cells by JCV. Glial cells were
incubated with 5HT, MDL100.907, SB206553, ketanserin, or ritanserin. Cells were challenged and
scored for viral infection as described above. 5HT, MDL100.907, ketanserin, and ritanserin all
significantly inhibited infection. SB206553 had a modest inhibitory effect on JCV infection.
Fig. 2. (A) Antibodies directed at
5HT2AR or 5HT2C R, but not
antibodies directed at dopamine
receptors, inhibit JCV infection
of glial cells. Glial cells were in-
cubated with antibodies against
either serotonin receptors or
dopamine receptors as indicated.
The cells were then challenged
with JCV and infection scored at
72 hours after infection by indi-
rect immunofluorescence analy-
sis of V antigen–expressing cells.
The percentage of infected cells
in untreated cultures was set at
100%. If antibodies to 5HT2AR
or 5HT2C R were added at 24
hours after infection, they had
no effect on virus infection. (B)
Antibodies directed at 5HT2AR
or 5HT2C R do not inhibit infec-
tion of glial cells by SV40, as
indicated.
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fection. Glial cells were pre-incubated with
equivalent amounts of each antibody and
then challenged with JCV. None of the anti-
bodies to dopamine receptors specifically
inhibited infection of glial cells by JCV
(Fig. 2A). In contrast, the antibodies to both
5HT
2A
R and 5HT
2C
R significantly in-
hibited infection (Fig. 2A). These antibodies
had no effect on infection if added 24 hours
after infection (Fig. 2A). As a control for
specificity, we pre-incubated glial cells
with antibodies to 5HT
2A
R or 5HT
2C
R
and then challenged with the related virus,
SV40. These antibodies had no significant
effect on infection of glial cells by SV40
(Fig. 2B).
We next asked if we could rescue
infection in 5HT
2A
receptor–negative cells
by transient and/or stable expression of a
5HT
2A
receptor clone. HeLa cells did not
express either 5HT
2A
or 5HT
2C
receptors but
expressed abundant levels of D1, D2, D2s,
and D3 dopamine receptors (Fig. 3A). We
transiently transfected HeLa cells with
p5HT
2A
R or a control vector, and at 24
hours after transfection the cells were in-
fected with JCV at an MOI of 10.0. Infection
was assayed 48 hours after infection. HeLa
cells transfected with the control construct
(mock) remained refractory to JCV infection
(Fig. 3B). In contrast, HeLa cells transfected
with the 5HT
2A
receptor clone became sus-
ceptible to infection (Fig. 3B). The percent-
age of infected cells was low (5%) but
consistent with the low transfection efficien-
cy of HeLa cells. We next established a
HeLa cell line stably expressing the 5HT
2A
receptor by cotransfection of p5HT
2A
R with
a plasmid encoding resistance to puromycin
(pMSCVpuro) (Fig. 3C). HeLa-5HT
2A
R
cells were then challenged with JCV in the
presence and absence of antibodies to
5HT
2A
R. The HeLa-5HT
2A
R cells were
readily infected by JCV at levels comparable
to infection in SVG-A glial cells (Fig. 3C).
Infection of both cell types by JCV was
blocked by antibody to 5HT
2A
R (Fig. 3C).
Glial cells were transfected with a GFP-
tagged 5HT
2A
receptor clone and then
incubated with Alexa-fluor 594–labeled
JCV at 24 hours after transfection when
GFP expression was maximal (26). Virus
binding was first synchronized by incubation
with the cells at 4-C for 30 min. The cells
were then either fixed immediately or
warmed to 37-C for 5 min or 30 min and
then fixed. When the cells were allowed to
internalize virus at 37-C for 5 min or 30 min,
strong colocalization between the virus and
the 5HT
2A
receptors was seen (Fig. 4). The
virus appeared to initially interact only with
the alpha 2-6–linked sialic acid component
of the JCV receptor, and then at 37-C
interacted with the 5HT
2A
receptor. This
second interaction most likely leads to
efficient and rapid virus internalization. This
is not unexpected, because both JCV and
5HT
2A
receptors are rapidly internalized by
clathrin-dependent endocytosis after ligand
binding. This is also consistent with the fact
that JCV internalization is accompanied by
activation of the MAP kinases ERKs1 and 2,
because serotonin binding to 5HT
2A
recep-
tors also activates ERKs 1 and 2 (12, 27, 28).
Compared with other polyomaviruses,
JCV has a very restricted tropism, infecting
Fig. 3. (A) HeLa cells express dopamine
receptors but do not express 5HT2A or
5HT2c serotonergic receptors. HeLa cells
were incubated with irrelevant antibody
(solid histograms), with monoclonal anti-
bodies to the 5HT2AR and 5HT2C R (top
panels, open histograms), or with poly-
clonal antibodies to the D1, D2, D2s, and
D3 dopamine receptors (middle and bot-
tom panels, open histograms). Antibody
binding was detected with either goat
anti-mouse or goat anti-rabbit secondary
antibodies conjugated to AlexaFluor-488.
(B) Transient transfection of HeLa cells
with the 5HT2A receptor rescues virus
infection. HeLa cells were untreated,
transfected with irrelevant plasmid DNA
(mock), or with a 5HT2A receptor–expressing
plasmid. At 24 hours after transfection,
the cells were challenged with JCV and
infection scored 48 hours later by indirect
immunofluorescent analysis of T antigen–
expressing cells. The cells were counter-
stained with Evans blue, which fluoresces
red in the ultraviolet channel. T antigen–
expressing cells could only be detected in
HeLa cells transfected with the 5HT2A
receptor clone. The percentage of T
antigen–positive cells is indicated in pa-
rentheses. (C) Stable transfection of HeLa cells with the 5HT2A receptor
rescues virus infection. (Top panel) Analysis of 5HT2AR expression on
HeLa cells stably expressing 5HT2AR (HeLa-5HT2AR). (Middle panel)
HeLa-5HT2AR cells infected with JCV and stained for T antigen. The
percentage of infected cells is indicated in parentheses. (Bottom panel)
Infection of SVG-A and HeLa-5HT2AR cells by JCV is blocked by
antibodies to 5HT2AR. The percentage of infected SVG-A and HeLa-
5HT2AR cells in nonspecific antibody–treated controls is indicated in
parentheses. The amount of infection in the control samples was set at
100% for comparison.
Fig. 4. Colocalization of JCV and
5HT2A receptor at different
stages of virus internalization.
(A) Glial cells were transiently
transfected with a 5HT2AR-GFP
serotonin receptor construct, and
the fusion protein was visualized
by confocal microscopy. (B and
C) 5HT2AR-GFP–expressing cells
were exposed to AlexaFluor-
594–labeled JCV (red) and al-
lowed to internalize for 5 min
(B) or 30 min (C). At both time points, virus is shown to colocalize with the 5HT2A-GFP receptor
(yellow). Insets show an enlarged portion of the image identified by arrows. Scale bar, 10 m.
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oligodendrocytes, astrocytes, kidney epithe-
lial cells, and, to a limited extent, B lym-
phocytes. In vitro, the virus can only be
efficiently propagated in primary human fetal
glial cells or in human fetal glial cell lines
such as POJ and SVG (29–31). This restricted
tropism is due to the presence or absence of
cell-type-specific transcription and replication
factors and to the presence of specific virus
receptors. HeLa cells are completely refracto-
ry to infection by JCV but will support early
viral gene expression when transfected with
JCV DNA. HeLa cells express the JCV
receptor–type sialic acid (a 2-6 SA) and bind
virus as well as permissive glial cells,
suggesting that sialic acid is not sufficient
for mediating virus infection (32). Our ability
to rescue JCV infection in receptor-negative
HeLa cells by transiently or stably introducing
the 5HT
2A
receptor demonstrates that
5HT
2A
R is a functional entry receptor for
JCV. The breadth of other serotonergic
receptors that might also function as JCV
receptors has not been thoroughly investigat-
ed, but preliminary data have ruled out the
5HT1, 5HT3, and 5HT7 families.
Neurons express abundant levels of sero-
tonin receptors but are generally refractory
to infection by JCV. However, neurons do
not express the receptor-type sialic acid for
JCV, which indicates that infection of cells
requires both components of the JCV recep-
tor (9). Oligodendrocytes, astrocytes, B
lymphocytes, and kidney epithelial cells all
express both the alpha 2-6–linked sialic acid
component of the JCV receptor and 5HT
2A
receptors (9, 33–39).
5HT2-family receptors are highly ex-
pressed on brain microvasculature, on as-
trocytes at the blood-brain barrier, and in
brain regions lacking the blood-brain barrier,
such as the area postrema and the choroid
plexus. This raises the possibility that JCV
may directly traffic to the CNS via the blood
under viremic conditions, as occurs during
severe and prolonged immunosuppression.
Finally, serotonin receptor agonists and
antagonists are widely used to treat a
variety of neurological and psychiatric
disorders. Drugs that have been developed
to treat PML have all been hampered by
poor bioavailability in the CNS, a problem
not inherent to serotonergic inhibitors.
Prophylactic treatment of HIV-infected
patients with serotonergic antagonists may
prevent the spread of JCV to the CNS and
the development of PML. Aggressive
therapeutic treatment of patients with
PML may reduce viral spread within the
CNS and prevent additional episodes of
demyelination.
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Fat Mobilization in Adipose Tissue
Is Promoted by Adipose
Triglyceride Lipase
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Mobilization of fatty acids from triglyceride stores in adipose tissue requires
lipolytic enzymes. Dysfunctional lipolysis affects energy homeostasis and may
contribute to the pathogenesis of obesity and insulin resistance. Until now,
hormone-sensitive lipase (HSL) was the only enzyme known to hydrolyze
triglycerides in mammalian adipose tissue. Here, we report that a second
enzyme, adipose triglyceride lipase (ATGL), catalyzes the initial step in
triglyceride hydrolysis. It is interesting that ATGL contains a ‘‘patatin domain’’
common to plant acyl-hydrolases. ATGL is highly expressed in adipose tissue of
mice and humans. It exhibits high substrate specificity for triacylglycerol and is
associated with lipid droplets. Inhibition of ATGL markedly decreases total
adipose acyl-hydrolase activity. Thus, ATGL and HSL coordinately catabolize
stored triglycerides in adipose tissue of mammals.
Animals, seed plants, and fungi commonly
store excessive amounts of energy sub-
strates in the form of intracellular triglyc-
eride (TG) deposits. In mammals, TGs are
stored in adipose tissue, where they provide
the primary source of energy during peri-
www.sciencemag.org SCIENCE VOL 306 19 NOVEMBER 2004 1383
R E P O R T S
o
n
 M
arch 28, 2018
 
http://science.sciencem
ag.org/
D
ow
nloaded from
 
The Human Polyomavirus, JCV, Uses Serotonin Receptors to Infect Cells
Megan Stanifer, Anushree Bhatnagar, Wesley K. Kroeze, Bryan L. Roth and Walter J. Atwood
Gwendolyn F. Elphick, William Querbes, Joslynn A. Jordan, Gretchen V. Gee, Sylvia Eash, Kate Manley, Aisling Dugan,
DOI: 10.1126/science.1103492
 (5700), 1380-1383.306Science 
ARTICLE TOOLS http://science.sciencemag.org/content/306/5700/1380
MATERIALS
SUPPLEMENTARY http://science.sciencemag.org/content/suppl/2004/11/17/306.5700.1380.DC1
CONTENT
RELATED 
http://stke.sciencemag.org/content/sigtrans/2004/260/tw425.abstract
http://science.sciencemag.org/content/sci/309/5733/381.2.full
REFERENCES
http://science.sciencemag.org/content/306/5700/1380#BIBL
This article cites 38 articles, 17 of which you can access for free
PERMISSIONS http://www.sciencemag.org/help/reprints-and-permissions
Terms of ServiceUse of this article is subject to the 
 is a registered trademark of AAAS.Science
licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. The title 
Science, 1200 New York Avenue NW, Washington, DC 20005. 2017 © The Authors, some rights reserved; exclusive 
(print ISSN 0036-8075; online ISSN 1095-9203) is published by the American Association for the Advancement ofScience 
o
n
 M
arch 28, 2018
 
http://science.sciencem
ag.org/
D
ow
nloaded from
 
